TLRY — Tilray Brands, Inc.

Tilray Brands (TLRY) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Revenue: Record $218 million for Q2 2026, up from prior periods, driven by strong international cannabis and Tilray Pharma performance.
• Adjusted EBITDA: $8.4 million, slightly down from $9 million year-over-year.
• Net Loss: $43.5 million, improved from a loss of $85.3 million in the same quarter last year.
• Cash Position: Ended the quarter with approximately $292 million in cash and marketable securities, resulting in a net cash position exceeding debt by nearly $30 million.
• Adjusted EPS: Reported loss of $0.02, reflecting a reverse stock split impact.

2. Strategic Updates and Business Highlights:

• International Growth: International cannabis revenue grew 51% sequentially, reaching $20 million, with a focus on expanding operations in Europe, particularly Germany, the U.K., and Poland.
• Tilray Pharma Expansion: Revenue increased by 26% year-over-year to $85 million, with plans to triple pharmacy distribution in Germany.
• Canadian Market Leadership: Continued dominance in the Canadian cannabis market, with adult-use sales reaching $46 million and a focus on premium product offerings.
• Beverage Segment: Revenue totaled $50 million, with ongoing integration and optimization efforts under Project 420 aimed at improving margins and operational efficiency.
• Wellness Products: Revenue flat at $14.6 million, driven by innovation in health-focused products.

3. Forward Guidance and Outlook:

• Adjusted EBITDA Guidance: Reaffirmed for FY 2026 at $62 million to $72 million.
• International Cannabis Revenue Target: Expected to reach an annual run rate of approximately $150 million.
• Canadian Market Growth: Anticipated mid- to high single-digit growth in Canadian cannabis sales, supported by new product launches and market demand.

4. Bad News, Challenges, or Points of Concern:

• Regulatory Risks: Potential upcoming bans on intoxicating hemp products in the U.S. could impact growth; management is actively lobbying for regulatory changes.
• Price Compression: Continued price pressures in the Canadian market, particularly in lower-margin categories like vapes and pre-rolls.
• Integration Challenges: Ongoing integration of beverage brands has not yet yielded expected results, with some segments experiencing declines in sales and profit margins.
• Operational Headwinds: Challenges in the Canadian wholesale market and a strike in British Columbia affected sales performance.

5. Notable Q&A Insights:

• Regulatory Engagement: Management is working with lawmakers to address potential bans on hemp-derived products and is optimistic about achieving favorable outcomes.
• Supply Management: The company is strategically holding back supply from the Canadian market to focus on higher-margin international sales.
• Market Share Dynamics: While there was slight market share growth in Canada, competitive pressures remain a concern, particularly from international players entering the German market.
• Long-term Beverage Strategy: Management remains confident in the beverage segment's potential, particularly with the anticipated legalization of THC beverages in the U.S., and is focused on leveraging existing infrastructure for future growth.

Overall, Tilray Brands reported strong financial results and strategic advancements, particularly in international markets, while facing challenges related to regulatory pressures and competitive dynamics in the cannabis and beverage sectors.